Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Eli Lilly has amassed a market value nearing a trillion dollars based on the assumption that demand for its new weight-loss ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...

Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...

Eli Lilly LLY will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.03 billion and $1.53 per share, ...

In interviews with Reuters, eight U.S. obesity specialists at universities and large health systems described a different ...

Eli Lilly And Co LLY experienced a 1.37% increase in pre-market trading on Wednesday, as per Benzinga Pro. This uptick occurs ...

Mounjaro sales more than doubled to $3.11 billion from $1.41 billion a year ago. The U.S. pharma giant reported third-quarter ...